139 related articles for article (PubMed ID: 8942490)
21. Pregnancy following GnRH agonist therapy of uterine leiomyoma obstructing a single fallopian tube.
Ben-Ami M; Battino S; Shalev E
Hum Reprod; 1993 May; 8(5):780-1. PubMed ID: 8314977
[TBL] [Abstract][Full Text] [Related]
22. Estriol add-back therapy in the long-acting gonadotropin-releasing hormone agonist treatment of uterine leiomyomata.
Nakayama H; Yano T; Sagara Y; Kikuchi A; Ando K; Wang Y; Watanabe M; Matsumi H; Osuga Y; Momoeda M; Taketani Y
Gynecol Endocrinol; 1999 Dec; 13(6):382-9. PubMed ID: 10685331
[TBL] [Abstract][Full Text] [Related]
23. The effects of add-back therapy with tibolone on myoma uteri.
Göçmen A; Kara IH; Karaca M
Clin Exp Obstet Gynecol; 2002; 29(3):222-4. PubMed ID: 12519049
[TBL] [Abstract][Full Text] [Related]
24. Medical treatment of uterine myoma with long-acting gonadotropin-releasing hormone agonist prior to myomectomy.
Liu CH; Lin YS; Lin CC; Tzeng CC; Chou CY
J Formos Med Assoc; 1993 Jun; 92(6):536-9. PubMed ID: 8106041
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety considerations in women with uterine leiomyomas treated with gonadotropin-releasing hormone agonists: the estrogen threshold hypothesis.
Friedman AJ; Lobel SM; Rein MS; Barbieri RL
Am J Obstet Gynecol; 1990 Oct; 163(4 Pt 1):1114-9. PubMed ID: 2145765
[TBL] [Abstract][Full Text] [Related]
26. Beneficial effects of dienogest on uterine myoma volume: a retrospective controlled study comparing with gonadotropin-releasing hormone agonist.
Ichigo S; Takagi H; Matsunami K; Suzuki N; Imai A
Arch Gynecol Obstet; 2011 Sep; 284(3):667-70. PubMed ID: 21052701
[TBL] [Abstract][Full Text] [Related]
27. Preoperative treatment of uterine leiomyomas: clinical findings and expression of transforming growth factor-beta3 and connective tissue growth factor.
De Falco M; Staibano S; D'Armiento FP; Mascolo M; Salvatore G; Busiello A; Carbone IF; Pollio F; Di Lieto A
J Soc Gynecol Investig; 2006 May; 13(4):297-303. PubMed ID: 16697947
[TBL] [Abstract][Full Text] [Related]
28. Differential effect of gonadotropin-releasing hormone analogue treatment on estrogen levels and sulfatase activity in uterine leiomyoma and myometrium.
van de Ven J; Donker TH; Blankenstein MA; Thijssen JH
Fertil Steril; 2002 Jun; 77(6):1227-32. PubMed ID: 12057733
[TBL] [Abstract][Full Text] [Related]
29. Shrinkage effect of gonadotropin releasing hormone agonist treatment on uterine leiomyomas and t(12;14).
Takahashi K; Kawamura N; Ishiko O; Ogita S
Int J Oncol; 2002 Feb; 20(2):279-83. PubMed ID: 11788889
[TBL] [Abstract][Full Text] [Related]
30. Raloxifene prevents the growth of uterine leiomyomas in premenopausal women.
Jirecek S; Lee A; Pavo I; Crans G; Eppel W; Wenzl R
Fertil Steril; 2004 Jan; 81(1):132-6. PubMed ID: 14711556
[TBL] [Abstract][Full Text] [Related]
31. Uterine adenocarcinoma after GnRH agonist treatment.
Dessole S; Ruiu GA; Cherchi PL; Ambrosini G
Arch Gynecol Obstet; 2000 Feb; 263(3):148-9. PubMed ID: 10763848
[TBL] [Abstract][Full Text] [Related]
32. Ultrastructural comparison of uterine leiomyoma cells from the same myoma nodule before and after gonadotropin-releasing hormone agonist treatment.
Ito F; Kawamura N; Ichimura T; Tsujimura A; Ishiko O; Ogita S
Fertil Steril; 2001 Jan; 75(1):125-30. PubMed ID: 11163826
[TBL] [Abstract][Full Text] [Related]
33. Treatment of uterine fibroids with implants of gonadotropin-releasing hormone agonist: assessment by hysterography.
Donnez J; Schrurs B; Gillerot S; Sandow J; Clerckx F
Fertil Steril; 1989 Jun; 51(6):947-50. PubMed ID: 2498131
[TBL] [Abstract][Full Text] [Related]
34. Subcutaneous injection or infusion of gonadotropin releasing-hormone agonist buserelin in the treatment of enlarged uteri harboring leiomyomata.
Franssen AM; Willemsen WN; Corbey RS; Doesburg WH; van 't Veen AJ; Rolland R
Eur J Obstet Gynecol Reprod Biol; 1991 Jul; 40(3):221-8. PubMed ID: 1908799
[TBL] [Abstract][Full Text] [Related]
35. Quantitative MRI of uterine leiomyomas during triptorelin treatment: reproducibility of volume assessment and predictability of treatment response.
Broekmans FJ; Heitbrink MA; Hompes PG; Schoute E; Falke T; Schoemaker J
Magn Reson Imaging; 1996; 14(10):1127-35. PubMed ID: 9065902
[TBL] [Abstract][Full Text] [Related]
36. Immunohistochemical detection of insulin-like growth factor type I receptor and uterine volume changes in gonadotropin-releasing hormone analog-treated uterine leiomyomas.
Di Lieto A; Iannotti F; De Falco M; Staibano S; Pollio F; Ciociola F; De Rosa G
Am J Obstet Gynecol; 2003 Mar; 188(3):702-6. PubMed ID: 12634644
[TBL] [Abstract][Full Text] [Related]
37. Pathological evaluation of uterine leiomyomas treated with gonadotropin-releasing hormone agonist (GnRH-a) therapy: role of mast cells and a possible mechanism of GnRH-a resistance in leiomyomas.
Nakayama M; Mitsuhashi T; Shimizu Y; Ishihara O; Shimizu M
Pathol Int; 2008 May; 58(5):268-74. PubMed ID: 18429824
[TBL] [Abstract][Full Text] [Related]
38. Relationship between platelet-derived growth factor expression in leiomyomas and uterine volume changes after gonadotropin-releasing hormone agonist treatment.
Di Lieto A; De Rosa G; De Falco M; Iannotti F; Staibano S; Pollio F; Scaramellino M; Salvatore G
Hum Pathol; 2002 Feb; 33(2):220-4. PubMed ID: 11957148
[TBL] [Abstract][Full Text] [Related]
39. Pre-surgical treatment of uterine myomas with LH-RH agonists.
D'Addato F; Repinto A; Andreoli C
Clin Exp Obstet Gynecol; 1992; 19(1):45-50. PubMed ID: 1535032
[TBL] [Abstract][Full Text] [Related]
40. Short term pituitary desensitization: effects of different doses of the gonadotrophin-releasing hormone agonist triptorelin.
Broekmans FJ; Hompes PG; Lambalk CB; Schoute E; Broeders A; Schoemaker J
Hum Reprod; 1996 Jan; 11(1):55-60. PubMed ID: 8671156
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
